Cancer Biotherapy and Radiopharmaceuticals
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 1.7 | Q3 | 37.3% | 0.498 | Q2 | 60.8% |
| 2024 | 2.1 | Q2 | 50.9% | 0.550 | Q2 | 65.5% |
| 2023 | 2.4 | Q2 | 62.0% | 0.607 | Q2 | 71.3% |
| 2022 | 3.4 | Q2 | 74.9% | 0.650 | Q2 | 74.5% |
| 2021 | 3.6 | Q2 | 70.5% | 0.592 | Q2 | 72.5% |
| 2020 | — | — | 0.716 | Q2 | 76.7% | |
| 2019 | — | — | 0.544 | Q2 | 69.8% | |
| 2018 | — | — | 0.545 | Q2 | 68.0% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1557-8852
ISSN
1084-9785
region
Northern America
coverage
1996-2026